Docetaxel (docetaxel) concentrate for infusions 20 mg/ml. 4 ml. (80 mg.) vial №1

$280.00

Manufacturer: Italy

Category:

Description

Docetaxel in combination with doxorubicin and cyclophosphamide is intended for adjuvant therapy of patients with: operable breast cancer with lymph node damage operable breast cancer without lymph node damage. Patients with operable breast cancer without lymph node involvement should receive adjuvant therapy if the patients are subject to chemotherapy in accordance with accepted international criteria for primary therapy of early stages of breast cancer. Docetaxel in combination with doxorubicin is intended for the treatment of patients with locally or metastatic breast cancer who have not previously received cytotoxic therapy for this disease. Docetaxel as a monotherapy is intended for the treatment of patients with locally or metastatic breast cancer after ineffective cytotoxic therapy, which included anthracycline or alkylvalnium. Docetaxel in combination with trastuzumab is intended for the treatment of patients with metastatic breast cancer with increased expression of NER-2 tumor cells who have not previously received chemotherapy for metastases. Docetaxel in combination with capecitabine is intended for the treatment of patients with locally or metastatic breast cancer after ineffective therapy that included anthracycline. Non-small cell lung cancer Docetaxel is indicated for the treatment of patients with locally or metastatic non-small cell lung cancer after ineffective chemotherapy with platinum preparations. In combination with cisplatin, docetaxel is indicated for the treatment of patients with locally inoperable or metastatic non-small cell lung cancer, if chemotherapy for this condition has not been performed. Head and neck cancer In combination with cisplatin and 5-fluorouracil, docetaxel is indicated for induction therapy of patients with locally squamous carcinoma in the head and neck. Prostate cancer In combination with prednisone or prednisolone, docetaxel is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer. adenocarcinoma of the stomach In combination with cisplatin and 5-fluorouracil, docetaxel is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including gastroesophageal adenocarcinoma, who have not previously received chemotherapy for metastases.